Squarepoint Ops LLC Acquires 29,722 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Squarepoint Ops LLC boosted its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 68.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,015 shares of the company’s stock after buying an additional 29,722 shares during the period. Squarepoint Ops LLC owned approximately 0.14% of PMV Pharmaceuticals worth $110,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in PMVP. BML Capital Management LLC grew its holdings in shares of PMV Pharmaceuticals by 105.3% during the 4th quarter. BML Capital Management LLC now owns 3,466,684 shares of the company’s stock worth $5,235,000 after purchasing an additional 1,777,912 shares in the last quarter. Stonepine Capital Management LLC bought a new position in PMV Pharmaceuticals in the fourth quarter worth $809,000. Two Sigma Investments LP lifted its position in PMV Pharmaceuticals by 5.0% in the fourth quarter. Two Sigma Investments LP now owns 506,986 shares of the company’s stock worth $766,000 after purchasing an additional 23,931 shares during the period. Aldebaran Capital LLC boosted its stake in PMV Pharmaceuticals by 14.6% during the fourth quarter. Aldebaran Capital LLC now owns 502,190 shares of the company’s stock worth $758,000 after buying an additional 63,938 shares in the last quarter. Finally, Peapod Lane Capital LLC acquired a new stake in PMV Pharmaceuticals during the fourth quarter worth $673,000. 90.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a research note on Thursday, March 20th.

PMV Pharmaceuticals Stock Performance

Shares of PMV Pharmaceuticals stock opened at $1.06 on Tuesday. The firm has a market cap of $55.07 million, a PE ratio of -1.06 and a beta of 1.43. The business’s 50 day simple moving average is $0.94 and its 200 day simple moving average is $1.25. PMV Pharmaceuticals, Inc. has a 52-week low of $0.81 and a 52-week high of $1.83.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. As a group, equities research analysts predict that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.